论文部分内容阅读
目的:观察吸入信必可都保(布地奈德/福莫特罗)对成人哮喘常规维持治疗的临床疗效。方法:对60例临床诊断为哮喘的轻中度成人患者应用吸入信必可都保(160μg/45μg/吸)常规维持治疗,每日2次,观察患者用药前及用药后2周、4周、12周的第1秒用力呼气容量(FEV1)、最大呼气峰值流速(PEF)等肺功能动态变化及治疗前后的总有效率。结果:治疗后患者肺功能明显提高,60例患者中临床控制26例(43.3%),显效16例(26.7%),好转11例(18.3%)。结论:信必可都保可改善肺功能,减轻气道炎症,提高控制率,在成人哮喘常规维持治疗中起效迅速,疗效确切,患者依从性好,值得临床推广应用。
OBJECTIVE: To observe the clinical effect of inhalation letter BTP (budesonide / formoterol) on routine maintenance treatment of adult asthma. Methods: Sixty patients with mild-to-moderate adult patients with asthma were randomly divided into two groups: control group (160μg / 45μg / inhalation) routinely received maintenance therapy twice a day for 2 weeks, 4 weeks , Dynamic expiratory volume at 1 second of 12 weeks (FEV1), maximum expiratory peak flow (PEF) and other pulmonary function dynamic changes and the total effective rate before and after treatment. Results: After treatment, pulmonary function was significantly improved in 26 patients (43.3%), marked improvement in 16 patients (26.7%) and improvement in 11 patients (18.3%). Conclusion: SBP can improve pulmonary function, reduce airway inflammation and improve the control rate. It has a rapid onset of efficacy and good curative effect in routine maintenance treatment of adult asthma. It is worthy of clinical application.